Either compete incompetence or a disregard for the rules of engagement for ASX listed companies and minority shareholders. Embarrassing for all involved, particularly the Australian base 'independent directors'. ASM will also depart from Australia with their tails between their legs, I doubt they'll warmly received as a shareholder of any other Australian company in the future. Do they try for a sneaky delisting, if so another blow for minorities. In my opinion DNA ends with a class action, this is the type of stuff the ambulance chasers live for.
DNA Price at posting:
3.1¢ Sentiment: Sell Disclosure: Not Held
